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Abstract: The mammalian eye is protected against pathogens and inﬂ  ammation in a relatively 
immune-privileged environment. Stringent mechanisms are activated that regulate external 
injury, infection, and autoimmunity. The eye contains a variety of cells expressing vasoactive 
neuropeptides (VNs), and their receptors, located in the sclera, cornea, iris, ciliary body, 
ciliary process, and the retina. VNs are important activators of adenylate cyclase, deriving 
cyclic adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). Impairment 
of VN function would arguably impede cAMP production and impede utilization of ATP. 
Thus VN autoimmunity may be an etiological factor in retinopathy involving perturbations 
of purinergic signaling. A sound blood supply is necessary for the existence and functional 
properties of the retina. This paper postulates that impairments in the endothelial barriers and 
the blood–retinal barrier, as well as certain inﬂ  ammatory responses, may arise from disruption 
to VN function. Phosphodiesterase inhibitors and purinergic modulators may have a role in the 
treatment of postulated VN autoimmune retinopathy.
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Background
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating 
polypeptide (PACAP) are vasoactive neuropeptides (VNs) that have been shown 
to exist in the mammalian eye in areas such as the sclera, cornea, iris, ciliary body, 
ciliary process, and the retina.1,2 An important feature of VN receptors is their ability to 
activate adenylate cyclase (AC) to produce cyclic adenosine monophosphate (cAMP) 
from adenosine triphosphate (ATP) in the retina of mammals.3 VN receptors are 
class II G protein-coupled receptors (GPCRs) and are important for regulating levels 
of ATP and cAMP.4 Additionally, ATP is a vasoactive signal in the microvasculature 
of the rat retina5 and cAMP regulates neurological metabolism by inﬂ  uencing 
blood–brain (BBB) and blood–retinal (BRB) barrier permeability, coordination 
of neuroregulatory pathways, and inducing protection against neuronal apoptosis. 
However failure to metabolize ATP adequately may result in elevated extracellular 
ATP levels and set in train perturbations of purinergic signaling initiating signiﬁ  cant 
neuro- and retino-toxicity.6,7
PACAP also acts as a neurotransmitter in the retinohypothalamic tract mediating 
photic regulation of the brain’s biological clock8 and, along with other neuropep-
tides, is likely to be of signiﬁ  cance in other parts of the eye9 in addition to the retina. 
Moreover PACAP has protective effects on monosodium glutamate (MSG)-induced 
retinal degeneration10 and kainic acid retinal degeneration.11 PACAP and glutamate are 
co-stored in the retinohypothalamic tract12 and PACAP attenuates glutamate-induced 
neurotoxicity in cultured retinal neurons,13 which suggests that compromise of this VN 
would have signiﬁ  cant detrimental impact on retinal viability and function.Clinical Ophthalmology 2009:3 260
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As PACAP has a role in the relaxation of pericytes, this 
may form the basis for a diagnostic procedure for diabetic 
retinopathy.14 In view of the vasodilatory roles of these 
VNs along with hypoxia protection, they may have a place 
in the prevention of ischemic retinal degeneration.15 VIP 
and PACAP are likely to have an important role in retinal 
development.16 PACAP and VIP autoimmunity has been 
hypothesized previously as a causal agent in retinopathy.17 
VN function and postulated autoimmunity is an emerging 
ﬁ  eld and may be relevant to clinical ophthalmologists because 
of the opportunity to develop novel treatments.
Retinal pathology 
and autoimmunity
Retinal pathology may arise as a consequence of autoimmunity. 
For example, peripheral vitreo-chorioretinal dystrophies 
(PVCRD) have been shown to arise from localized reactions, 
noting that self antibodies were detected in 70% of PVCRD 
cases with normal levels of immune complexes in the blood.18 
Antibody-induced apoptosis is a possible mechanism for 
retinal pathology. Antibodies such as antirecoverin can 
induce retinopathy by exerting cytotoxic effects on retinal 
cells. Activation of the caspase 3-dependent apoptotic path-
way occurs with the resultant effect of retinal photoreceptor 
cell death, degeneration of the photoreceptor layer, and 
loss of sight.19 Additionally the presence of anti-recoverin 
immunoreactivity may be a possible causal factor in some 
patients with retinal pathologies.20
Importantly viruses such as coronavirus exacerbate retinal 
degeneration in murine models with retinal disease; this 
manifests as retinal vasculitis and the presence of anti-retinal 
antibodies.21 Acute inﬂ  ammation and BRB compromise 
occur in the early stages of the disease in these mice while 
autoimmune reactivity and neurodegeneration are features 
of the later stages of retinal disease.22 These ﬁ  ndings support 
some involvement of autoimmunity in the mechanism of 
retinal degeneration.
The signiﬁ  cant contribution of cAMP function in the 
BRB suggests retinal pathologies could involve VN autoim-
munity. Stabilization of BRB function may be associated 
with nitric oxide, phosphodiesterase enzymes (PDEs)23 
and cAMP regulation.24 Failure to metabolize ATP to 
cAMP could result in perturbation of purinergic signaling 
in the retina. Indeed, other causes of ATP elevation and 
subsequent pathology have been demonstrated.25 Purinergic 
activation may promote the effects of diabetes-induced 
increase in the vulnerability of retinal microvessels and be 
a previously unrecognized mechanism by which diabetic 
retinopathy progresses.26 Certainly ATP participates in 
bi-directional signaling between glial cells and the retina27 
and gliosis may impede recovery from repair of retinal 
detachment.28
The present hypothesis postulates that cAMP relies 
extensively on PACAP/VIP activation of AC and that 
compromise of their function would result in impaired cAMP 
derivation from ATP. ATP is implicated as an endogenous 
trigger of microglial activation, and reactive gliosis may 
affect microglia, neurons, and oligodendrocytes.29 Microg-
lial activation might be exacerbated under conditions 
of trauma and hypoxia30,31 and impaired metabolism of 
intracellular ATP may lead to extravasation of ATP to the 
extracellular compartment. While ectonucleotidases are 
responsible for metabolizing extracellular ATP, its utiliza-
tion and availability is determined by the balance of release 
and removal by enzymatic degradation and uptake.32 This 
mechanism may result in perturbation of purinergic signaling. 
Thus a pathomechanism involving ATP toxicity may occur 
with potentially serious consequences.
Implications for treatment 
interventions
Retinopathy may occur from VN autoimmunity which 
impedes cAMP production while elevating ATP levels. 
Theoretically phosphodiesterase inhibitor (PDEI) therapy 
may assist in restoring cAMP levels, however ATP toxicity 
may remain an issue and purinergic antagonists may act to 
protect retinal neurodegeneration from ATP toxicity.33 Impor-
tantly, PDEIs are effective in regulating cAMP. Interestingly, 
PDEIs also enhance tyrosine hydroxylase phenotypes of 
dopaminergic cells, which are important during retinal 
development.34 Inhibitors of PDE4 could be considered as a 
candidate for therapeutic drugs to treat diseases associated 
with disorders of retinal circulation without severe cardio-
vascular side-effects,35 although care should be taken with 
the use of PDE5 inhibitors.36 Nevertheless, a case may exist 
for undertaking a therapeutic trial of cAMP-speciﬁ  c PDE 
inhibitors in retinopathies resulting from VN autoimmunity 
should this pathology subsequently be proven.
A possible association of VN autoimmunity with reti-
nopathy in humans seems plausible and suggests the need 
for further research. Speciﬁ  c therapeutic interventions may 
already be available or could be developed for the preven-
tion and treatment of VN autoimmune retinopathy. Recent 
evidence suggests that VIP may be useful in the treatment 
of experimental autoimmune uveoretinitis (EAU). The 
possibility of vasoactive neuropeptides acting in a therapeutic Clinical Ophthalmology 2009:3 261
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context may support the hypothesis of VN impairment as 
an etiology in retinal pathology.37
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